SUPPLEMENT
Q3 2021 — Sales of Key Products/Franchises
Q3 2021PDF · 6 pages197 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 686 $ 601 14.0% 14.0% - 1,960 $ 1,917 2.2% 2.2% - Intl 686 541 26.9% 22.8% 4.1% 1,894 1,722 10.0% 3.9% 6.1% WW 1,372 1,142 20.1% 18.2% 1.9% 3,854 3,639 5.9% 3.0% 2.9% SKIN HEALTH / BEAUTY US 569 572 -0.5% -0.5% - 1,862 1,767 5.4% 5.4% - Intl 555 577 -3.8% -5.5% 1.7% 1,595 1,506 5.9% 2.1% 3.8% WW 1,124 1,149 -2.2% -3.0% 0.8% 3,457 3,273 5.6% 3.9% 1.7% ORAL CARE US 150 164 -8.4% -8.4% - 478 510 -6.2% -6.2% - Intl 248 248 0.1% -1.8% 1.9% 762 694 9.9% 5.9% 4.0% WW 398 412 -3.3% -4.5% 1.2% 1,240 1,204 3.0% 0.8% 2.2% BABY CARE US 95 91 5.2% 5.2% - 288 279 3.3% 3.3% - Intl 296 302 -2.0% -3.1% 1.1% 879 831 5.8% 4.6% 1.2% WW 391 393 -0.3% -1.2% 0.9% 1,167 1,110 5.2% 4.3% 0.9% WOMEN'S HEALTH US 3 3 20.1% 20.1% - 9 10 -5.7% -5.7% - Intl 229 227 0.5% 0.6% -0.1% 675 654 3.1% 2.3% 0.8% WW 232 230 0.8% 0.8% 0.0% 684 664 3.0% 2.1% 0.9% WOUND CARE / OTHER US 122 125 -2.6% -2.6% - 390 370 5.3% 5.3% - Intl 61 64 -5.2% -9.0% 3.8% 186 175 5.8% 0.0% 5.8% WW 182 189 -3.5% -4.8% 1.3% 575 545 5.4% 3.6% 1.8% TOTAL CONSUMER HEALTH US 1,625 1,556 4.5% 4.5% - 4,987 4,853 2.8% 2.8% - Intl 2,075 1,958 5.9% 3.7% 2.2% 5,991 5,582 7.3% 3.5% 3.8% WW 3,700 $ 3,514 5.3% 4.1% 1.2% 10,978 $ 10,435 5.2% 3.1% 2.1% See footnotes at end of schedule % Change % Change -- 1 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS PHARMACEUTICAL SEGMENT (2,3) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency IMMUNOLOGY US 2,771 $ 2,558 8.3% 8.3% - 7,932 $ 7,330 8.2% 8.2% - Intl 1,480 1,230 20.3% 18.8% 1.5% 4,464 3,619 23.3% 17.6% 5.7% WW 4,250 3,789 12.2% 11.7% 0.5% 12,395 10,950 13.2% 11.3% 1.9% REMICADE US 480 634 -24.3% -24.3% - 1,508 1,852 -18.6% -18.6% - US Exports (4) 47 78 -40.2% -40.2% - 197 321 -38.7% -38.7% - Intl 234 209 12.2% 8.1% 4.1% 721 673 7.1% 1.4% 5.7% WW 761 921 -17.4% -18.3% 0.9% 2,426 2,846 -14.8% -16.1% 1.3% SIMPONI / SIMPONI ARIA US 295 312 -5.3% -5.3% - 840 840 0.0% 0.0% - Intl 276 280 -1.1% -0.7% -0.4% 877 827 6.1% 2.8% 3.3% WW 571 592 -3.3% -3.1% -0.2% 1,717 1,667 3.0% 1.4% 1.6% STELARA US 1,569 1,313 19.5% 19.5% - 4,396 3,668 19.9% 19.9% - Intl 809 634 27.7% 26.3% 1.4% 2,404 1,795 33.9% 27.5% 6.4% WW 2,378 1,947 22.2% 21.7% 0.5% 6,800 5,463 24.5% 22.4% 2.1% TREMFYA US 376 222 69.7% 69.7% - 975 650 50.1% 50.1% - Intl 161 105 52.5% 50.5% 2.0% 459 316 45.4% 38.0% 7.4% WW 537 327 64.1% 63.5% 0.6% 1,434 965 48.5% 46.1% 2.4% OTHER IMMUNOLOGY US 3 - * * - 15 - * * - Intl 0 3 * * * 3 9 -68.6% -70.8% 2.2% WW 3 3 -26.4% -27.5% 1.1% 18 9 91.6% 89.5% 2.1% INFECTIOUS DISEASES US 679 413 64.3% 64.3% - 1,635 1,265 29.2% 29.2% - Intl 709 451 57.2% 55.6% 1.6% 1,788 1,397 28.0% 23.2% 4.8% WW 1,389 864 60.6% 59.8% 0.8% 3,424 2,662 28.6% 26.1% 2.5% COVID-19 VACCINE US 270 - * * - 421 - * * - Intl 233 - * * - 346 - * * - WW 502 - * * - 766 - * * - EDURANT / rilpivirine US 12 11 8.4% 8.4% - 31 33 -4.8% -4.8% - Intl 247 226 9.7% 8.7% 1.0% 733 684 7.2% 1.7% 5.5% WW 259 236 9.6% 8.6% 1.0% 764 716 6.7% 1.4% 5.3% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 380 379 0.4% 0.4% - 1,128 1,154 -2.2% -2.2% - Intl 137 147 -7.1% -8.8% 1.7% 440 461 -4.6% -8.6% 4.0% WW 517 526 -1.7% -2.2% 0.5% 1,568 1,615 -2.9% -4.1% 1.2% OTHER INFECTIOUS DISEASES US 18 24 -26.0% -26.0% - 55 79 -29.6% -29.6% - Intl 93 78 18.3% 15.2% 3.1% 270 252 6.9% 2.6% 4.3% WW 110 102 7.8% 5.4% 2.4% 325 331 -1.8% -5.0% 3.2% % Change % Change -- 2 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency NEUROSCIENCE US 835 759 10.2% 10.2% - 2,448 2,285 7.2% 7.2% - Intl 854 846 0.8% -0.5% 1.3% 2,770 2,565 8.0% 4.1% 3.9% WW 1,689 1,605 5.3% 4.6% 0.7% 5,218 4,850 7.6% 5.5% 2.1% CONCERTA / Methylphenidate US 35 43 -19.5% -19.5% - 117 150 -22.1% -22.1% - Intl 122 107 14.2% 12.5% 1.7% 372 319 16.4% 11.6% 4.8% WW 157 149 4.5% 3.3% 1.2% 489 469 4.1% 0.8% 3.3% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 648 585 11.0% 11.0% - 1,882 1,704 10.4% 10.4% - Intl 355 341 4.3% 3.2% 1.1% 1,111 983 13.0% 7.6% 5.4% WW 1,004 926 8.5% 8.1% 0.4% 2,994 2,688 11.4% 9.4% 2.0% RISPERDAL CONSTA US 71 70 1.3% 1.3% - 210 220 -4.7% -4.7% - Intl 69 81 -16.7% -16.0% -0.7% 242 254 -5.1% -8.3% 3.2% WW 140 152 -8.4% -8.0% -0.4% 452 475 -4.9% -6.6% 1.7% OTHER NEUROSCIENCE US 81 60 34.7% 34.7% - 239 210 13.9% 13.9% - Intl 307 317 -2.9% -4.8% 1.9% 1,045 1,008 3.7% 1.5% 2.2% WW 388 377 3.1% 1.5% 1.6% 1,284 1,218 5.5% 3.6% 1.9% ONCOLOGY US 1,525 1,267 20.3% 20.3% - 4,364 3,623 20.4% 20.4% - Intl 2,140 1,862 14.9% 13.8% 1.1% 6,406 5,310 20.6% 15.3% 5.3% WW 3,665 3,129 17.1% 16.5% 0.6% 10,770 8,933 20.6% 17.4% 3.2% DARZALEX US 841 585 43.7% 43.7% - 2,302 1,540 49.5% 49.5% - Intl 739 514 43.7% 42.0% 1.7% 2,076 1,397 48.6% 42.2% 6.4% WW 1,580 1,099 43.7% 42.9% 0.8% 4,378 2,937 49.1% 46.0% 3.1% ERLEADA US 214 152 40.5% 40.5% - 578 407 41.8% 41.8% - Intl 130 55 * * * 329 112 * * * WW 344 206 66.7% 65.8% 0.9% 907 519 74.7% 72.2% 2.5% IMBRUVICA US 413 450 -8.3% -8.3% - 1,311 1,329 -1.3% -1.3% - Intl 654 581 12.6% 10.9% 1.7% 1,996 1,682 18.7% 13.1% 5.6% WW 1,066 1,031 3.5% 2.5% 1.0% 3,307 3,011 9.9% 6.7% 3.2% ZYTIGA / abiraterone acetate US 25 58 -57.0% -57.0% - 96 284 -66.2% -66.2% - Intl 523 532 -1.8% -2.1% 0.3% 1,653 1,564 5.7% 0.9% 4.8% WW 548 590 -7.2% -7.5% 0.3% 1,749 1,848 -5.4% -9.4% 4.0% OTHER ONCOLOGY US 32 21 49.6% 49.6% - 76 63 21.0% 21.0% - Intl 94 181 -48.0% -47.2% -0.8% 352 556 -36.6% -38.5% 1.9% WW 126 203 -37.6% -36.9% -0.7% 428 619 -30.7% -32.4% 1.7% % Change % Change -- 3 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency PULMONARY HYPERTENSION US 610 510 19.7% 19.7% - 1,778 1,541 15.4% 15.4% - Intl 258 239 7.9% 8.4% -0.5% 821 742 10.7% 7.3% 3.4% WW 868 749 15.9% 16.1% -0.2% 2,599 2,283 13.9% 12.7% 1.2% OPSUMIT US 299 244 22.8% 22.8% - 861 729 18.2% 18.2% - Intl 159 148 7.4% 7.8% -0.4% 510 458 11.3% 7.7% 3.6% WW 458 392 17.0% 17.1% -0.1% 1,371 1,187 15.5% 14.1% 1.4% UPTRAVI US 265 226 17.3% 17.3% - 792 692 14.6% 14.6% - Intl 44 34 30.4% 28.8% 1.6% 135 100 34.6% 27.9% 6.7% WW 309 260 19.0% 18.8% 0.2% 927 792 17.1% 16.2% 0.9% OTHER PULMONARY HYPERTENSION US 47 40 14.4% 14.4% - 125 121 2.8% 2.8% - Intl 54 57 -4.4% -2.1% -2.3% 176 183 -3.7% -5.0% 1.3% WW 101 97 3.4% 4.8% -1.4% 301 304 -1.1% -1.9% 0.8% CARDIOVASCULAR / METABOLISM / OTHER US 800 931 -14.0% -14.0% - 2,379 2,574 -7.6% -7.6% - Intl 333 351 -5.1% -8.2% 3.1% 1,007 1,052 -4.2% -9.3% 5.1% WW 1,133 1,281 -11.5% -12.4% 0.9% 3,386 3,625 -6.6% -8.1% 1.5% XARELTO US 636 630 0.8% 0.8% - 1,794 1,716 4.5% 4.5% - Intl - - - - - - - - - - WW 636 630 0.8% 0.8% - 1,794 1,716 4.5% 4.5% - INVOKANA / INVOKAMET US 66 156 -57.4% -57.4% - 249 405 -38.4% -38.4% - Intl 67 68 -1.0% -4.3% 3.3% 194 173 11.9% 5.8% 6.1% WW 133 224 -40.3% -41.3% 1.0% 443 578 -23.4% -25.2% 1.8% PROCRIT / EPREX US 47 69 -30.9% -30.9% - 168 215 -21.7% -21.7% - Intl 65 63 3.1% 0.5% 2.6% 198 208 -4.7% -9.7% 5.0% WW 112 132 -14.6% -15.8% 1.2% 366 423 -13.4% -15.8% 2.4% OTHER US 51 75 -32.6% -32.6% - 168 238 -29.3% -29.3% - Intl 200 219 -8.7% -11.9% 3.2% 615 670 -8.3% -13.1% 4.8% WW 251 294 -14.8% -17.2% 2.4% 783 908 -13.8% -17.3% 3.5% TOTAL PHARMACEUTICAL US 7,221 6,438 12.2% 12.2% - 20,536 18,619 10.3% 10.3% - Intl 5,773 4,980 15.9% 14.6% 1.3% 17,256 14,685 17.5% 12.5% 5.0% WW 12,994 $ 11,418 13.8% 13.2% 0.6% 37,792 $ 33,304 13.5% 11.3% 2.2% % Change % Change -- 4 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS MEDICAL DEVICES SEGMENT (2) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 444 $ 399 11.1% 11.1% - 1,353 1,019 32.7% 32.7% - Intl 513 437 17.7% 15.1% 2.6% 1,599 1,134 41.1% 34.3% 6.8% WW 957 836 14.5% 13.2% 1.3% 2,952 2,153 37.1% 33.6% 3.5% ORTHOPAEDICS US 1,249 1,308 -4.5% -4.5% - 3,821 3,427 11.5% 11.5% - Intl 843 774 8.8% 6.8% 2.0% 2,611 2,145 21.7% 15.4% 6.3% WW 2,093 2,083 0.5% -0.3% 0.8% 6,433 5,572 15.4% 13.0% 2.4% HIPS US 210 221 -5.3% -5.3% - 654 564 15.9% 15.9% - Intl 146 124 18.8% 16.0% 2.8% 451 344 31.3% 24.1% 7.2% WW 356 345 3.3% 2.3% 1.0% 1,105 908 21.8% 19.0% 2.8% KNEES US 184 205 -9.8% -9.8% - 579 527 10.0% 10.0% - Intl 131 102 28.1% 25.9% 2.2% 403 298 35.4% 28.2% 7.2% WW 316 308 2.8% 2.1% 0.7% 983 825 19.2% 16.6% 2.6% TRAUMA US 455 433 5.3% 5.3% - 1,352 1,194 13.3% 13.3% - Intl 260 253 2.4% 0.9% 1.5% 805 698 15.2% 9.5% 5.7% WW 715 685 4.2% 3.7% 0.5% 2,157 1,892 14.0% 11.9% 2.1% SPINE, SPORTS & OTHER US 400 449 -11.1% -11.1% - 1,236 1,142 8.2% 8.2% - Intl 306 295 3.5% 1.5% 2.0% 952 805 18.2% 12.0% 6.2% WW 705 745 -5.3% -6.1% 0.8% 2,187 1,947 12.3% 9.7% 2.6% % Change % Change -- 5 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) THIRD QUARTER NINE MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency SURGERY US 948 913 3.9% 3.9% - 2,881 2,247 28.2% 28.2% - Intl 1,457 1,239 17.6% 14.8% 2.8% 4,418 3,556 24.2% 18.4% 5.8% WW 2,405 2,152 11.8% 10.2% 1.6% 7,299 5,803 25.8% 22.2% 3.6% ADVANCED US 440 421 4.6% 4.6% - 1,304 1,079 20.9% 20.9% - Intl 705 579 21.8% 18.4% 3.4% 2,126 1,644 29.3% 23.1% 6.2% WW 1,144 1,000 14.6% 12.6% 2.0% 3,430 2,723 26.0% 22.2% 3.8% GENERAL US 508 492 3.3% 3.3% - 1,577 1,168 35.0% 35.0% - Intl 752 660 13.9% 11.7% 2.2% 2,292 1,912 19.9% 14.5% 5.4% WW 1,261 1,152 9.4% 8.1% 1.3% 3,869 3,080 25.6% 22.3% 3.3% VISION US 475 473 0.6% 0.6% - 1,414 1,160 21.9% 21.9% - Intl 714 608 17.4% 17.4% 0.0% 2,103 1,683 25.0% 22.0% 3.0% WW 1,189 1,081 10.1% 10.0% 0.1% 3,517 2,843 23.7% 22.0% 1.7% CONTACT LENSES / OTHER US 359 375 -4.3% -4.3% - 1,082 924 17.0% 17.0% - Intl 522 455 14.9% 15.2% -0.3% 1,525 1,274 19.8% 17.3% 2.5% WW 882 830 6.2% 6.4% -0.2% 2,607 2,198 18.6% 17.2% 1.4% SURGICAL US 117 98 19.6% 19.6% - 333 236 41.1% 41.1% - Intl 191 153 24.7% 23.7% 1.0% 577 409 41.1% 36.7% 4.4% WW 308 251 22.7% 22.1% 0.6% 910 645 41.1% 38.3% 2.8% TOTAL MEDICAL DEVICES US 3,117 3,092 0.8% 0.8% - 9,470 7,852 20.6% 20.6% - Intl 3,527 3,058 15.4% 13.3% 2.1% 10,731 8,518 26.0% 20.5% 5.5% WW 6,644 $ 6,150 8.0% 7.0% 1.0% 20,201 $ 16,370 23.4% 20.5% 2.9% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. % Change % Change -- 6 of 6 --